AngioDynamics (ANGO) Tops Q1 EPS by 2c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
September 30, 2021 7:00 AM EDTFiscal 2022 First Quarter Highlights
Net sales of $77.0 million increased 9.6% compared to the prior-year quarter Gross margin of 52.1% increased 120 basis points year over year GAAP loss per share of $0.18, and adjusted loss per share of $0.02 The Company commenced a Limited Market Release of its AlphaVac Mechanical Thrombectomy device in SeptemberLATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and... More
